Cipla, a global pharmaceutical company, has entered into a collaboration with ImmunoACT to commercialize Talicabtagene Autoleucel across key African territories. The agreement grants Cipla, through its subsidiary Medpro Pharmaceutica, exclusive marketing and distribution rights in South Africa, Algeria, and Morocco, while ImmunoACT will oversee manufacturing operations.
Talicabtagene Autoleucel is an autologous anti CD19 CAR-T therapy developed for patients diagnosed with relapsed or refractory B cell Non Hodgkin’s Lymphoma and B cell Acute Lymphoblastic Leukemia who have shown inadequate response to conventional treatment regimens. The therapy represents India’s first domestically developed CAR-T platform and has been administered to more than 500 patients in India. Clinical data from these administrations indicate sustained response rates and a safety profile consistent with global CAR-T benchmarks.
The partnership is positioned to address substantial unmet oncology needs across African healthcare systems. By focusing on cost rationalization, including the reduction of ancillary treatment expenses, the collaboration aims to enhance access to advanced cell therapies in markets where affordability remains a critical barrier.
Cipla’s leadership has highlighted the strategic significance of expanding its oncology portfolio through this alliance, reinforcing the company’s objective of broadening access to advanced therapeutics. Regional leadership has emphasized the opportunity to strengthen cancer care infrastructure in Africa through the introduction of locally developed innovation. ImmunoACT’s founders have also underscored the milestone of extending an indigenous CAR-T platform beyond India into international markets.
The collaboration reflects a broader industry movement toward decentralizing high complexity biologics manufacturing and improving geographic accessibility of cell and gene therapies. By integrating manufacturing expertise with established regional distribution capabilities, Cipla and ImmunoACT are advancing a scalable model for delivering advanced oncology treatments in emerging markets.